Theravance Biopharma to Participate in an Upcoming Investor Conference

Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) will participate in the Evercore ISI 4th Annual HEALTHCONx Virtual Conference on November 30, 2021, at 11:20 am ET. The webcast can be accessed under the Investors section on Theravance.com and will be available for 30 days afterward. The biopharmaceutical company focuses on developing respiratory medicines, including the FDA-approved YUPELRI (revefenacin) for treating COPD. The company aims to enhance patient lives through innovative respiratory therapies.

DUBLIN, Nov. 18, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicines, will participate in a fireside chat as follows: 

• Evercore ISI 4^th Annual HEALTHCONx Virtual Conference on Tuesday, November 30, at 11:20 am ET (8:20 am PT/4:20 pm GMT)

Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Presentations and Events. Replay of the webcast will be archived on the Company's website for 30 days.

About Theravance Biopharma

Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicines. Its core purpose is to create medicines that help improve the lives of patients suffering from respiratory illness.

In pursuit of its purpose, Theravance Biopharma leverages decades of respiratory expertise to discover and develop transformational medicines that make a difference. These efforts have led to the development of FDA-approved YUPELRI^® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its respiratory pipeline of internally discovered programs is targeted to address significant patient respiratory needs.

Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA^®, THERAVANCE^®, and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the US and certain other countries).

YUPELRI^® is a registered trademark of Mylan Specialty L.P., a Viatris Company. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.

Contact Information:
Contact: Gail B. Cohen
Corporate Communications / 917-214-6603

View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-301427456.html

SOURCE Theravance Biopharma, Inc.

FAQ

When will Theravance Biopharma participate in the Evercore ISI conference?

Theravance Biopharma will participate in the Evercore ISI 4th Annual HEALTHCONx Virtual Conference on November 30, 2021, at 11:20 am ET.

How can I access the Theravance Biopharma conference webcast?

The webcast of the Theravance Biopharma conference can be accessed through the Investors section of Theravance.com.

What is the focus of Theravance Biopharma?

Theravance Biopharma primarily focuses on the discovery, development, and commercialization of respiratory medicines.

What is YUPELRI and its indication?

YUPELRI (revefenacin) is an FDA-approved inhalation solution indicated for the maintenance treatment of patients with COPD.

How long will the conference replay be available?

The replay of the conference webcast will be archived on Theravance.com for 30 days.